INC Research Announces Pricing of Initial Public Offering

Stock expected to begin trading Nov. 7 on The Nasdaq Global Market under ticker symbol "INCR"

 

Raleigh, N.C., Nov. 6, 2014 - INC Research Holdings, Inc. (INC Research), a leading, global Phase I to IV contract research organization, today announced the pricing of its initial public offering of 8,108,108 shares of its Class A common stock at a price to the public of $18.50 per share. The shares of INC Research's Class A common stock are expected to begin trading on The Nasdaq Global Market under the ticker symbol "INCR" on Nov. 7, 2014.

Goldman, Sachs & Co. and Credit Suisse served as joint lead book-running managers for the offering. Baird, Wells Fargo Securities and William Blair served as co-managers for the offering. 

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on Nov. 6, 2014. The offering of these securities was made only by means of a prospectus, copies of which may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 866-471-2526, email: [email protected]; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, phone: 800-221-1037, email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About INC Research

INC Research is a leading global contract research organization (CRO) providing the full range ofPhase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertiseacross multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. We were ranked "Top CRO to Work With" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries.

Contact:
Investors: Ronnie Speight, +1 919 745 2745; Media: Lori Dorer, +1 513 345 1685

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.